- Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test
- Veracyte to Present at 20th Annual Needham Virtual Healthcare Conference
- Veracyte Appoints Muna Bhanji to Its Board of Directors
- Veracyte Completes Acquisition of Decipher Biosciences
- Veracyte Commends New USPSTF Lung Cancer Screening Guidelines
- Veracyte to Present at 10th Annual SVB Leerink Global Healthcare Conference
- Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results
- Veracyte to Present at BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- Veracyte to Release Fourth Quarter and Full-Year 2020 Financial Results on February 17, 2021
- Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Veracyte Inc (12V:DEU) closed at 46.40, -32.26% below its 52-week high of 68.50, set on Feb 09, 2021.
19.50Apr 21 202068.50Feb 09 2021
Markit short selling activity
|Market cap||3.59bn USD|
|EPS (TTM)||-0.6686 |
Data delayed at least 15 minutes, as of Apr 15 2021 16:10 BST.